I

Intercept Pharmaceuticals Inc
F:I4P

Watchlist Manager
Intercept Pharmaceuticals Inc
F:I4P
Watchlist
Price: 17.52 EUR Market Closed
Market Cap: 732.8m EUR
Have any thoughts about
Intercept Pharmaceuticals Inc?
Write Note

Intercept Pharmaceuticals Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Intercept Pharmaceuticals Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
I
Intercept Pharmaceuticals Inc
F:I4P
Revenue
$317.7m
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
69%
Abbvie Inc
NYSE:ABBV
Revenue
$55.5B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$28.3B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Revenue
$32.5B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$10.6B
CAGR 3-Years
14%
CAGR 5-Years
24%
CAGR 10-Years
30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.8B
CAGR 3-Years
1%
CAGR 5-Years
16%
CAGR 10-Years
18%

Intercept Pharmaceuticals Inc
Revenue Breakdown

Breakdown by Geography
Intercept Pharmaceuticals Inc

Not Available

Breakdown by Segments
Intercept Pharmaceuticals Inc

Total Revenue: 285.7m USD
100%
Product: 285.7m USD
100%

See Also

What is Intercept Pharmaceuticals Inc's Revenue?
Revenue
317.7m USD

Based on the financial report for Sep 30, 2023, Intercept Pharmaceuticals Inc's Revenue amounts to 317.7m USD.

What is Intercept Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 10Y
69%

Over the last year, the Revenue growth was 15%. The average annual Revenue growth rates for Intercept Pharmaceuticals Inc have been 2% over the past three years , 14% over the past five years , and 69% over the past ten years .

Back to Top